Norihito Kawasaki

Title: Norihito Kawasaki: Innovator in Liposome Targeting Compounds

Introduction

Norihito Kawasaki is a prominent inventor based in San Diego, California. He has made significant contributions to the field of biomedical research, particularly in the development of liposome targeting compounds. His innovative work focuses on enhancing the delivery of therapeutic agents to specific cells, which has important implications for medical treatments.

Latest Patents

Kawasaki holds a patent for "Liposome targeting compounds and related uses." This invention provides liposome targeting compounds designed to target cells that express sialic acid binding Ig-like lectin (Siglec). The liposome compounds typically include a binding moiety that acts as a glycan ligand for the Siglec on the target cell. Additionally, these compounds can encapsulate biological agents, such as antigens or therapeutic agents, which can be delivered to the target cell to modulate or eliminate it. The invention also outlines methods for using these liposome targeting compounds for targeted delivery of antigens and for modulating immune cells or immune responses.

Career Highlights

Kawasaki is affiliated with The Scripps Research Institute, where he conducts his research and development work. His innovative approach to liposome technology has positioned him as a key figure in the field of targeted drug delivery.

Collaborations

Kawasaki has collaborated with notable researchers, including James C. Paulson and Weihsu Chen. These collaborations have further advanced the research and application of liposome targeting compounds.

Conclusion

Norihito Kawasaki's contributions to the field of liposome targeting compounds demonstrate his commitment to advancing biomedical research. His innovative patent has the potential to significantly impact targeted therapies in medicine.